What future for Lag3 blockade?
Opdualag chalks up another failure, this time in the extension of an approved use.
ASCO-GU – Pfizer eyes broader Talzenna use
But the overall survival benefit in prostate cancer is still driven by HRR mutations.
ASCO-GU – some backing for Pfizer's EZH2 plan
Phase 1 data give investors a benchmark for mevrometostat's pivotal Mevpro-1 trial.
ASCO-GU – Pfizer looks for bigger bladder cancer invasion
Padcev still looks good in first-line bladder, but Pfizer hopes to make a mark in muscle-invasive disease.
Orca heads to the FDA
Orca-T is said to hit in a pivotal trial, but the comparator regimen could be debated.
Kura’s Komet fizzles
The company heralds a pivotal win with its menin inhibitor, but investors want to see data.
Pfizer drops its B7-H4 conjugate
Felmetatug vedotin’s exit could be bad news for Mersana.
